Patent application number | Description | Published |
20110028547 | NOVEL USE OF CAPSIATE OR DIHYDROCAPSIDATE - The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity. | 02-03-2011 |
20110065176 | HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF - The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. | 03-17-2011 |
20130245117 | NOVEL USE OF CAPSIATE OR DIHYDROCAPSIDATE - The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity. | 09-19-2013 |
20140275488 | HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF - The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. | 09-18-2014 |
20140288274 | HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF - The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. | 09-25-2014 |
Patent application number | Description | Published |
20080245961 | Nanowire Assisted Laser Desorption/Ionization Mass Spectrometric Analysis - This invention relates to a nanowire-assisted method for mass spectrometric analysis of a specimen. More specifically, by using nanowire which can fix a specimen and perform desorption/ionization of the specimen while effectively transferring laser energy to the specimen to be irradiated, thereby enabling to perform mass spectrometric analysis without using a matrix solution. This invention, by effectively performing desorption/ionization of a specimen using the above-mentioned nanowire, enables to effectively perform qualitative-, quantitative-, and micro-analyses of specimens as well as low molecular weighted specimens. Further, this invention enables to the typical device of mass spectrometric analysis used in MALDI-T of MS. In particular, this invention can perform mass spectrometric analysis of a specimen with molecular weight of less than 1,000 Da and perform quantitative analysis by fixing a specimen with a predetermined area. | 10-09-2008 |
20090261438 | VISIBLE-RANGE SEMICONDUCTOR NANOWIRE-BASED PHOTOSENSOR AND METHOD FOR MANUFACTURING THE SAME - A semiconductor nanowire-based photosensor includes a substrate, at least a top surface of the substrate being formed of an insulator, two electrodes spaced at a predetermined interval apart from each other on the substrate, metal catalyst layers disposed respectively on the two electrodes, and visible-range semiconductor nanowires grown from the metal catalyst layers on the two electrodes. The semiconductor nanowires grown from one of the metal catalyst layers are in contact with the semiconductor nanowires grown from the other metal catalyst layer, while the semiconductor nanowires grown respectively from the metal catalyst layers on the two electrodes are floated between the two electrodes over the substrate. | 10-22-2009 |
20120264144 | METHOD FOR BINDING A RECOMBINANT POLYPEPTIDE TO A CARRIER - The present invention refers to a method for binding a recombinant polypeptide to a carrier, wherein a layer is bound to a carrier, and the layer comprises a recombinant polypeptide on the surface distal to the carrier. | 10-18-2012 |
Patent application number | Description | Published |
20110096101 | LIQUID CRYSTAL DISPLAY AND METHOD FOR DRIVING THE SAME - A liquid crystal display includes a liquid crystal display panel including data lines and gate lines, a data driving circuit configured to drive the data lines, a gate driving circuit configured to drive the gate lines, a timing controller configured to divide a unit frame period into a first sub-frame period and a second sub-frame period, a backlight unit configured to provide light to the liquid crystal display panel wherein the backlight unit includes a plurality of light sources, and a light source driving circuit configured to turn off all the plurality of light sources during the first sub-frame period and turns on all the plurality of light sources at a turn-on time within the second sub-frame period. | 04-28-2011 |
20110157260 | 3D IMAGE DISPLAY DEVICE - A 3-dimensional (3D) image display device includes a liquid crystal panel configured to alternately display a left-eye image and a right-eye image in a cycle of unit frame period, a data driving circuit configured to drive data lines of the liquid crystal panel, a gate driving circuit configured to drive gate lines of the liquid crystal panel, a timing controller configured to divide the unit frame period into N sub-frame periods for each of the left-eye image and the right-eye image, where N is an integer equal to or greater than 2, a plurality of light sources configured to generate light to be radiated to the liquid crystal panel, a light source control circuit configured to generate a backlight control signal to control a turn-on time of the plurality of light sources, and a light source driving circuit configured to turn off all the light sources during a first N-1 subframe periods and turn on all the light sources during a last subframe period. | 06-30-2011 |
Patent application number | Description | Published |
20100214331 | BACKLIGHT UNIT FOR LIQUID CRYSTAL DISPLAY DEVICE AND DRIVING METHOD OF THE SAME - A backlight unit for a liquid crystal display device includes a reflection plate, a light guide plate over the reflection plate, the light guide plate having n grooves at a lower surface and including (n+1) areas divided by the grooves, wherein n is a natural number, a first LED assembly disposed at a first side surface of the light guide plate, the first LED assembly including (n+1) LED packages, each of which has at least one LED, wherein the LED packages of the first LED assembly correspond to the areas, respectively, and are separately driven, and a plurality of optical sheets over the light guide plate. | 08-26-2010 |
20110140615 | APPARATUS AND METHOD OF DRIVING LIGHT SOURCE - A light source driving apparatus for implementing general purpose driving of a high-current light emitting diode (LED) and a low-current LED, and a method for driving the same are disclosed. The apparatus for driving the light source includes a plurality of light emitting diode (LED) strings, and a light emitting diode (LED) driving circuit for driving the LED strings, and having a plurality of channels commonly connected to the same LED string. | 06-16-2011 |
Patent application number | Description | Published |
20130308170 | HIGH SPEED HOLOGRAM RECORDING APPARATUS AND METHOD - A high speed hologram recording apparatus and method. The hologram recording apparatus includes: a light source for emitting coherent light; a beam splitter for splitting the coherent light emitted from the light source into a signal beam and a reference beam; a signal beam transfer unit comprising an angular deflector that changes a direction of the signal beam according to time, and irradiating the signal beam onto a hologram recording medium; and a reference beam transfer unit irradiating the reference beam at a location of the hologram recording medium where the signal beam is also irradiated. | 11-21-2013 |
20140055830 | PHASE MASK AND HOLOGRAPHIC RECORDING APPARATUS EMPLOYING THE SAME - A phase mask includes a phase modulation layer that modulates a phase of different portions of incident light, differently, such that a different optical phase delay, in a range between 0 and 2π is imparted to different portions of the incident light. A hologram recording apparatus includes a light source; a signal beam optical system that divides a beam emitted from the light source into a reference beam and a signal beam, modulates the signal beam according to hologram pixel information, and radiates the signal beam onto a hologram recording medium. The signal beam optical system includes the phase mask. The hologram recording apparatus also includes a reference beam optical system that radiates the reference beam onto the hologram recording medium. | 02-27-2014 |
20140063578 | APPARATUS FOR RECORDING AND REPRODUCING HOLOGRAM - A hologram recording and reproducing apparatus including: a coherent light source; a beam splitter which splits a beam emitted from the coherent light source into a signal beam and a reference beam; a signal beam forming unit which modulates the signal beam split and directs the modulated signal beam onto a hologram recording medium; and a reference beam forming unit which directs the reference beam to be irradiated onto a location on the hologram recording medium which overlaps with a location on the hologram recording medium on which the signal beam is incident, wherein the signal beam forming unit includes: a first light guide member which transmits the signal beam split by the beam splitter; a spatial light modulator (SLM) which modulates the signal beam transmitted through the first light guide member; and a holographic Fourier transformation optical device which focuses the modulated signal beam onto the hologram recording medium. | 03-06-2014 |
20140127611 | PHOTOPOLYMER COMPOSITION FOR RECORDING HOLOGRAM, AND PHOTOPOLYMER LAYER AND HOLOGRAM RECORDING MEDIA INCLUDING THE SAME - A photopolymer composition includes a polymer binder; a monomer for holographic recording; a photoinitiation system including an electron acceptor, at least one of an electron donor and a hydrogen atom donor, and a dye-sensitizer; and a solvent. The monomer for holographic recording includes N-acryloylthiomorpholine. | 05-08-2014 |
20140132999 | OPTICAL HEAD FOR HOLOGRAM OPTICAL APPARATUS AND METHOD OF OPERATING THE SAME - An optical head for a hologram optical apparatus and a method of operating the same are provided. The optical head for the hologram optical apparatus includes a reference light unit for guiding reference light, a signal light unit for guiding signal light, and a light source unit for providing 1 the reference light and the signal light to the reference light unit and the signal light unit, wherein the reference light unit and the signal light unit are stacked. The signal light unit includes: a plurality of optical waveguides stacked sequentially; composite hologram optical elements and lighting hologram optical elements disposed on the plurality of optical waveguides; an optical modulator for modulating light output from the plurality of the optical waveguides; and a lens for condensing light output from the optical modulator onto a recording layer. | 05-15-2014 |
20140133000 | PHOTOREFRACTIVE POLYMER COMPOSITE, AND PHOTOREFRACTIVE DEVICE AND HOLOGRAM DISPLAY DEVICE INCLUDING THE SAME - Provided are a photorefractive polymer composite, and a photorefractive devices and hologram display device including the same. The photorefractive polymer composite includes a photoconductive polymer matrix, a nonlinear optical chromophore, a plasticizer, and a graphite-based photocharge generator. | 05-15-2014 |
20140185115 | INTEGRATED HOLOGRAM OPTICAL DEVICE - An integrated hologram optical device, a method of manufacturing the same, and an integrated hologram recording apparatus are provided. The integrated hologram optical device includes a two-dimensional (2D) array of a plurality of hogels. A holographic element is configured to be recorded such that a combination of the plurality of hogels is configured to adjust at least one of an angle and a focal length of a signal beam. | 07-03-2014 |
20140253997 | ISLANDS-IN-SEA TYPE PHOTOREFRACTIVE POLYMER COMPOSITE, AND PHOTOREFRACTIVE DEVICE AND OPTICAL DEVICE INCLUDING THE SAME - Provided are an islands-in-sea type photorefractive polymer composite, and a photorefractive device and an optical device including the same. The islands-in-sea type photorefractive polymer composite includes at least a photoconductive polymer matrix, a nonlinear optical chromophore, and a plasticizer, as a sea component, and includes at least a photocharge generator as an island component. | 09-11-2014 |
20140285863 | METHOD AND APPARATUS FOR HOLOGRAPHIC RECORDING - Provided is a holographic recording method in which an interference fringe between a reference beam and a signal beam, modulated according to information regarding a plurality of hologram pixels, is recorded on a holographic recording medium, the holographic recording method including multiplexing-recording the interference fringe of the plurality of hologram pixels such that at least a part of the interference fringe recorded of neighboring hologram pixels of the plurality of hologram pixels is overlapped. | 09-25-2014 |
Patent application number | Description | Published |
20140128610 | R-7-(3-AMINOMETHYL-4-METHOXYIMINO-3-METHYL-PYRROLIDIN-1-YL)-1-CYCLOPROPYL-- 6-FLUORO-4-OXO-1,4-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID AND L-ASPARTIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR ANTIMICROBIAL - Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration. | 05-08-2014 |
20150105558 | R-7-(3-AMINOMETHYL-4-METHOXYIMINO-3-METHYL-PYRROLIDIN-1-YL)-1-CYCLOPROPYL-- 6-FLUORO-4-OXO-1,4-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID AND L-ASPARTIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR ANTIMICROBIAL - Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration. | 04-16-2015 |